At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AVDL Avadel Pharmaceuticals plc
Post-Market Trading 11-15 19:53:38 EST
10.91
-0.68
-5.87%
盘后10.75
-0.16-1.47%
17:12 EST
High11.61
Low10.62
Vol2.08M
Open11.57
D1 Closing11.59
Amplitude8.50%
Mkt Cap1.05B
Tradable Cap908.86M
Total Shares96.36M
T/O22.76M
T/O Rate2.49%
Tradable Shares83.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.